Marizomib is a novel irreversible brain-permeable proteasome inhibitor that inhibits CT-L (beta5), CT-T-laspase-like (C-L, beta1), and trypsin-like (T-L, beta2) 20S proteasomes with IC50s of 3.5, 28, and 430 nM.[3]
Molecular Weight:
313.78
Purity:
98.03%
CAS Number:
[437742-34-2]
Formula:
C15H20ClNO4
Target:
Proteasome
T16012
* VAT and and shipping costs not included. Errors and price changes excepted
